Dr. Jared Mataska, M.D.
What this data tells you about Dr. Mataska
Dr. Jared Mataska is a family medicine in Graham, TX, with 9 years in practice. Based on federal Medicare data, Dr. Mataska performed 9,777 Medicare services across 5,465 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mataska received a total of $2,285 from 30 pharmaceutical and/or device companies across 141 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in family medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mataska is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,200 | $18 | $30 |
| Office visit, established patient (30-39 min) | 920 | $82 | $250 |
| Blood draw (venipuncture) | 595 | $8 | $20 |
| Complete blood count (CBC) with differential | 583 | $8 | $40 |
| Office visit, established patient (20-29 min) | 547 | $59 | $170 |
| Comprehensive metabolic blood panel | 542 | $10 | $70 |
| Lipid panel (cholesterol and triglycerides) | 483 | $13 | $100 |
| Chronic care management, first 20 min/month | 401 | $47 | $122 |
| Betamethasone steroid injection | 390 | $4 | $25 |
| Advance care planning consultation, first 30 min | 300 | $76 | $253 |
| Annual alcohol misuse screening, 5 to 15 minutes | 297 | $18 | $53 |
| Annual depression screening | 280 | $18 | $75 |
| Annual wellness visit, follow-up | 273 | $123 | $275 |
| Drug injection, under skin or into muscle | 271 | $9 | $55 |
| Chest X-ray, 2 views | 235 | $21 | $95 |
| Infectious disease DNA/RNA test | 224 | $34 | $100 |
| Hemoglobin A1c test (diabetes monitoring) | 189 | $10 | $60 |
| Bone density scan (DEXA) | 158 | $36 | $335 |
| Remote patient monitoring management, 20 min/month | 142 | $35 | $149 |
| Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | 131 | $78 | $125 |
| Urinalysis with microscopic exam | 118 | $3 | $35 |
| Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | 113 | $140 | $1,100 |
| 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 113 | $50 | $100 |
| Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | 112 | $34 | $100 |
| Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique | 112 | $34 | $100 |
| Ceftriaxone antibiotic injection | 104 | $0 | $5 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 87 | $16 | $45 |
| Chronic care management, additional 20 min/month | 80 | $35 | $94 |
| Electrocardiogram (EKG), 12-lead | 76 | $10 | $75 |
| Urine microalbumin (protein) analysis | 64 | $6 | $45 |
| Creatinine test (kidney function) | 64 | $5 | $60 |
| Basic metabolic blood panel | 60 | $8 | $60 |
| Remote patient monitoring device, 30 days | 55 | $35 | $177 |
| New patient office visit (45-59 min) | 52 | $94 | $385 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 44 | $30 | $122 |
| Injection, ketorolac tromethamine, per 15 mg | 38 | $0 | $25 |
| X-ray of lower and sacral spine, 2-3 views | 27 | $23 | $110 |
| X-ray of knee, 1-2 views | 25 | $23 | $97 |
| Transitional care management services for problem of high complexity | 25 | $211 | $520 |
| Echocardiogram, transthoracic | 24 | $139 | $608 |
| Ultrasound study of arm and leg arteries | 24 | $48 | $246 |
| Ultrasound of heart, follow-up | 23 | $54 | $800 |
| Ultrasound of aorta, vena cava, groin vessels or bypass grafts | 23 | $82 | $351 |
| Test to measure expiratory airflow and volume | 21 | $20 | $103 |
| Joint injection, major joint | 20 | $50 | $180 |
| Testing for presence of drug, read by direct observation | 20 | $12 | $100 |
| Natriuretic peptide (heart and blood vessel protein) level | 19 | $38 | $200 |
| Hip X-ray, 2-3 views | 15 | $31 | $131 |
| Shoulder X-ray, 2+ views | 12 | $22 | $96 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 12 | $145 | $489 |
| Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report | 12 | $8 | $50 |
| X-ray of abdomen, 2 views | 11 | $28 | $104 |
| New patient office visit (30-44 min) | 11 | $45 | $250 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Mataska is a clinical cardiology specialist, with above-average Medicare volume (top 1% in TX), and low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Mataska experienced with denosumab injection (prolia/xgeva)?
Does Dr. Mataska receive payments from pharmaceutical companies?
How do Dr. Mataska's costs compare to other family medicines in Graham?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology